JPRN-UMIN000004798已完成未知
Discontinuation of tyrosine kinase inhibitor treatment in patients who have obtained complete molecular response after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia - Discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia
Keio University School of Medicine, Division of Hematology0 个研究点目标入组 70 人开始时间: 2011年1月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Has a history of AP/BC during TKI treatment 2)Cannot give written informed consent 3)Any patient whom the treating physician feels inappropriate for accrual
研究者
相似试验
进行中（未招募）
不适用
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)MedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2010-022946-25-Outside-EU/EEAChildren's Oncology Group195
招募中
4 期
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO): a prospective, multicentre, single-arm studychronic leukemiachronic myeloid leukemiaCML10018849NL-OMON52067Radboud Universitair Medisch Centrum140
进行中（未招募）
1 期
Continuing Access to the Tyrosine Kinase Inhibitor of VEGFR-2, AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical TrialsPatients who have been treated in previous AG-013736 oncology studiesEUCTR2005-000051-15-DEPfizer Pharma GmbH50
进行中（未招募）
1 期
Continuing Access to AG-013736 (A406) for Patients Previously Receiving AG-013736 in Clinical TrialsEUCTR2005-000051-15-CZPfizer Inc., 235 East 42nd Streeet, New York, NY 1001766
进行中（未招募）
不适用
CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2,AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 INCLINICAL TRIALSPatients who have been treated in previous AG-013736 oncology studies.MedDRA version: 14.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000051-15-ITPFIZER INC.39